Oppenheimer Weighs in on Trevena, Inc.’s FY2022 Earnings (NASDAQ:TRVN)

Trevena, Inc. (NASDAQ:TRVNGet Rating) – Equities researchers at Oppenheimer lifted their FY2022 earnings estimates for Trevena in a research note issued to investors on Wednesday, November 9th. Oppenheimer analyst J. Jones now expects that the biopharmaceutical company will post earnings of ($8.75) per share for the year, up from their prior estimate of ($9.25). The consensus estimate for Trevena’s current full-year earnings is ($8.83) per share. Oppenheimer also issued estimates for Trevena’s Q4 2022 earnings at ($2.00) EPS, Q1 2023 earnings at ($1.50) EPS, Q2 2023 earnings at ($1.50) EPS, Q3 2023 earnings at ($1.50) EPS, Q4 2023 earnings at ($1.25) EPS, FY2023 earnings at ($5.75) EPS, FY2024 earnings at ($6.00) EPS and FY2025 earnings at ($6.00) EPS.

Trevena (NASDAQ:TRVNGet Rating) last issued its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02.

A number of other equities analysts have also recently commented on TRVN. HC Wainwright reduced their price objective on shares of Trevena to $1.50 in a research report on Monday, August 15th. StockNews.com started coverage on shares of Trevena in a research report on Monday, November 7th. They set a “sell” rating for the company.

Trevena Trading Up 11.3 %

TRVN stock opened at $2.75 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.87 and a quick ratio of 5.55. The company has a fifty day moving average price of $0.28 and a two-hundred day moving average price of $0.29. Trevena has a one year low of $2.38 and a one year high of $23.51. The stock has a market cap of $19.10 million, a price-to-earnings ratio of -0.31 and a beta of 1.86.

Hedge Funds Weigh In On Trevena

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRVN. Cambridge Investment Research Advisors Inc. boosted its position in shares of Trevena by 133.3% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 65,858 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 37,633 shares during the period. Jane Street Group LLC bought a new stake in shares of Trevena in the second quarter valued at about $25,000. Virtu Financial LLC boosted its position in shares of Trevena by 72.7% in the third quarter. Virtu Financial LLC now owns 290,480 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 122,242 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Trevena in the second quarter valued at about $51,000. Finally, Renaissance Technologies LLC boosted its position in shares of Trevena by 90.8% in the first quarter. Renaissance Technologies LLC now owns 308,400 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 146,800 shares during the period. 12.34% of the stock is owned by institutional investors.

About Trevena

(Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Read More

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.